Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability

Background: Prognostic markers are needed to guide multiple sclerosis (MS) management in the context of large availability of disease-modifying drugs (DMDs). Objective: To investigate the role of cerebrospinal fluid (CSF) markers to inform long-term MS outcomes. Methods: Demographic features, IgM index, oligoclonal IgM bands (OCMB), lipid-specific OCMB, CSF neurofilament light chain protein levels, expanded disability status scale (EDSS), relapses and DMD use over the study period and peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell plus inner plexiform layer (GCIPL) thicknesses in non-optic neuritis eyes (end of follow-up) were collected from relapsing MS (RMS) patients with CSF obtained ⩽2 years after MS onset prospectively followed at the Hospital Clinic of Barcelona. We assessed associations between CSF markers and MS outcomes using multivariable models. Results: A total of 89 patients (71 females; median 32.9 years of age) followed over a median of 9.6 years were included. OCMB were associated with a 33% increase in the annualized relapse rate (ARR; p = 0.06), higher odds for high-efficacy DMDs use (OR = 4.8; 95% CI = (1.5, 16.1)), thinner pRNFL (β = −4.4; 95% CI = (−8.6, −0.2)) and GCIPL (β = −2.9; 95% CI = (−5.9, +0.05)), and higher rates to EDSS ⩾ 3.0 (HR = 4.4; 95% CI = (1.6, 11.8)) and EDSS ⩾ 4.0 (HR = 5.4; 95% CI = (1.1, 27.1)). No overall associations were found for other CSF markers. Conclusion: The presence of OCMB was associated with unfavorable long-term outcomes. OCMB should be determined in RMS to inform long-term prognosis.

[1]  M. Ramanathan,et al.  Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis , 2020, Multiple Sclerosis.

[2]  J. Frederiksen,et al.  Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis , 2020, Molecular Diagnosis & Therapy.

[3]  M. Amato,et al.  Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series , 2020, Multiple sclerosis.

[4]  L. Kappos,et al.  Neurofilament light levels are associated with long-term outcomes in multiple sclerosis , 2019, Multiple sclerosis.

[5]  S. Gil-Perotín,et al.  Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis , 2019, Front. Neurol..

[6]  F. Paul,et al.  Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis , 2019, Neurology.

[7]  P. Calabresi,et al.  Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[8]  M. Mühlau,et al.  CSF parameters associated with early MRI activity in patients with MS , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[9]  D. Hunt,et al.  Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  A. Oturai,et al.  Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis , 2018, Multiple sclerosis.

[11]  K. Blennow,et al.  Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis , 2018, Journal of Neuroinflammation.

[12]  H. Tumani,et al.  Intrathecal immunoglobulin M production: A promising high‐risk marker in clinically isolated syndrome patients , 2018, Annals of neurology.

[13]  G. Fenu,et al.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? , 2018, Journal of Neurology.

[14]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[15]  S. Ozakbas,et al.  Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results , 2017, Clinical Neurology and Neurosurgery.

[16]  Pablo Villoslada,et al.  The APOSTEL recommendations for reporting quantitative optical coherence tomography studies , 2016, Neurology.

[17]  J. Álvarez-cermeño,et al.  Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis , 2016, Journal of the Neurological Sciences.

[18]  T. Derfuss,et al.  Optimizing treatment success in multiple sclerosis , 2015, Journal of Neurology.

[19]  A. Muriel,et al.  Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis , 2015, European journal of neurology.

[20]  J. Ranjeva,et al.  Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual , 2012, Multiple sclerosis.

[21]  Axel Petzold,et al.  The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.

[22]  F. Cendes,et al.  Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study , 2012, Neuroimmunomodulation.

[23]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[24]  J. Gómez-Rial,et al.  Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis , 2008, Multiple sclerosis.

[25]  E. Merelli,et al.  A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.

[26]  F. Barkhof,et al.  Cerebrospinal Fluid IgM Index Correlates with Cranial MRI Lesion Load in Patients with Multiple Sclerosis , 2007, European Neurology.

[27]  M. Calabrese,et al.  Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  J. Masjuán,et al.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. , 2005, The Journal of clinical investigation.

[29]  J. Masjuán,et al.  Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS , 2002, Neurology.

[30]  J. Masjuán,et al.  A sensitive and reproducible method for the detection of oligoclonal IgM bands. , 2001, Journal of immunological methods.

[31]  P. Lambin,et al.  Frequency and relevance of IgM intrathecal synthesis in multiple sclerosis , 1995, European journal of neurology.

[32]  P. Monteyne,et al.  Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: An immunoaffinity-mediated capillary blot study , 1994, Journal of the Neurological Sciences.

[33]  E. Thompson,et al.  INTRATHECAL IMMUNOGLOBULIN M SYNTHESIS IN MULTIPLE SCLEROSIS , 1991 .

[34]  E. Thompson,et al.  Intrathecal synthesis of IgM in neurological diseases: A comparison between detection of oligoclonal bands and quantitative estimation , 1990, Journal of the Neurological Sciences.

[35]  X. Montalban,et al.  Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[36]  Angel Alberich-Bayarri,et al.  Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes , 2011, Neuroradiology.

[37]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.